
According to data from Benzinga Pro, during Q3, VistaGen Therapeutics's (NASDAQ:VTGN) reported sales totaled $357.90 thousand. Despite a 17.66% increase in earnings, the company posted a loss of $10.54 million. In Q2, VistaGen Therapeutics brought in $358.00 thousand in sales but lost $12.79 million in earnings.